Overview

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Status:
Withdrawn
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether temozolomide followed by nivolumab is an effective treatment for MMR-proficient colorectal cancer, while causing few or mild side effects.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
Nivolumab
Temozolomide